Editorials

ACS Guideline for the Early Detection of Cervical Cancer



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2003 Apr 15;67(8):1677-1680.

  Related Content

The American Cancer Society (ACS) recently published updated recommendations1 for the early detection of cervical cancer; this topic was last reviewed in 1987. The guidelines are based on a literature review combined with expert opinion when sufficient evidence was not available. In an effort to build consensus, several professional groups also were provided an opportunity to review and endorse these guidelines.

The ACS guidelines suggest a movement toward less excess screening and incorporation of emerging technologies when clinically feasible. The accompanying table on page 1678 compares the ACS guidelines with the U.S. Preventive Services Task Force (USPSTF) recommendations2 that appear in this issue of American Family Physician. The USPSTF strongly endorses the use of Papanicolaou (Pap) smears to detect premalignant and malignant lesions. It reaffirms cessation of screening at 65 years of age, recommends against Pap screening among women who have had hysterectomies for benign conditions, and in contrast with the ACS, concludes that there is insufficient evidence to assess the use of new technologies (e.g., thin-layer cytology, computerized screening, human papillomavirus [HPV] testing).

Advances in understanding the natural history of HPV infection and cervical cancer biology have revealed that HPV infections generally are transient. Among high-risk HPV subtypes, 70 percent of infections regress within two years,3 suggesting that less aggressive testing among younger women will allow for the spontaneous regression of HPV-associated abnormalities before screening is initiated.

The updated ACS guideline states that women over age 70 who have had three consecutive negative Pap tests over the prior 10 years may discontinue screening. As noted in the guideline, the decision mandates a discussion regarding the risks, benefits, and limitations of screening, as well as clinical judgment regarding other factors in a patient's medical history.

Although lacking in proven efficacy, vaginal cuff smears after hysterectomy for benign conditions appear to be a common clinical practice, accounting for untold medical costs and patient discomfort. The ACS guideline recommends against vaginal cytology testing after total hysterectomy for benign conditions when sufficient documentation is available. Women who have undergone a subtotal hysterectomy should continue standard cervical cancer screening. Patients with a history of cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) and patients for whom it is not possible to document the absence of CIN 2/3 should be screened until three documented, consecutive, technically satisfactory normal/negative cervical cytology tests are achieved within 10 years.

Comparison of Guidelines on Screening for Cervical Cancer

Criteria USPSTF guideline ACS guideline

Age to initiate screening

Optimum age unknown; within three years of onset of sexual activity or by age 21

Three years after the onset of sexual activity; no later than age 21

Screening frequency

At least every three years

Annually with conventional cytology or every two years with liquid-based cytology. After age 30, women with three consecutive normal tests may be screened every two to three years.

Screening after hysterectomy

No cytologic testing after total hysterectomy for benign condition

No cytologic testing after total hysterectomy for benign condition

Discontinuation of screening*

After age 65

After age 70

Routine screening for HPV infection

Insufficient evidence

Not yet approved by FDA. If approved, conventional cytology or liquid-based cytology combined with test for DNA from high-risk HPV subtypes should be performed not more often than every three years (preliminary recommendation)


USPSTF = U.S. Preventive Services Task Force; ACS = American Cancer Society; HPV = human papillomavirus; FDA = U.S. Food and Drug Administration.

*—For women with an intact cervix and consistently normal prior smears (see guidelines for specific definitions of “consistently normal prior smears”). Women with a history of cervical intraepithelial neoplasia grade 2 or 3, cervical cancer, or in utero diethylstilbestrol exposure, or women who are immunocompromised should continue screening unless deemed inappropriate because of significant comorbidity. Women who have tested positive for HPV should continue screening.

Information from references 1 and 2.

Comparison of Guidelines on Screening for Cervical Cancer

View Table

Comparison of Guidelines on Screening for Cervical Cancer

Criteria USPSTF guideline ACS guideline

Age to initiate screening

Optimum age unknown; within three years of onset of sexual activity or by age 21

Three years after the onset of sexual activity; no later than age 21

Screening frequency

At least every three years

Annually with conventional cytology or every two years with liquid-based cytology. After age 30, women with three consecutive normal tests may be screened every two to three years.

Screening after hysterectomy

No cytologic testing after total hysterectomy for benign condition

No cytologic testing after total hysterectomy for benign condition

Discontinuation of screening*

After age 65

After age 70

Routine screening for HPV infection

Insufficient evidence

Not yet approved by FDA. If approved, conventional cytology or liquid-based cytology combined with test for DNA from high-risk HPV subtypes should be performed not more often than every three years (preliminary recommendation)


USPSTF = U.S. Preventive Services Task Force; ACS = American Cancer Society; HPV = human papillomavirus; FDA = U.S. Food and Drug Administration.

*—For women with an intact cervix and consistently normal prior smears (see guidelines for specific definitions of “consistently normal prior smears”). Women with a history of cervical intraepithelial neoplasia grade 2 or 3, cervical cancer, or in utero diethylstilbestrol exposure, or women who are immunocompromised should continue screening unless deemed inappropriate because of significant comorbidity. Women who have tested positive for HPV should continue screening.

Information from references 1 and 2.

The ACS guideline also recommends that testing should be performed annually with conventional cervical cytology or every two years with liquid-based cytology, owing to the greater sensitivity of liquid-based tests. At or after age 30, women who have had three consecutive, technically satisfactory, normal/negative tests may be screened every two to three years unless there is a clinical contraindication to this approach. A history of normal/negative cytologic results has been shown to have a protective effect on cervical cancer incidence,4,5 probably as a result of the detection and treatment of various premalignant cervical lesions. Although many published studies examining liquid-based Pap technology appear to have some methodologic flaws, this test is an acceptable option for cervical cancer screening. Liquid-based Pap tests and conventional cytology yield similar percentages of satisfactory specimens.6

Although the U.S. Food and Drug Administration (FDA) has not approved HPV DNA testing for primary cervical cancer screening, this technology appears to be a promising adjunct to cytologic testing. The ACS guideline states that if the FDA approves HPV DNA testing (in combination with cytology) for cervical cancer screening, it is reasonable in women aged 30 years and older to perform cervical cancer screening every three years with conventional or liquid-based cytology in combination with a test for DNA from high-risk HPV subtypes. Combined cytology and HPV DNA testing should not be performed more often than every three years. Counseling and educating patients about the risks of HPV infection remains a priority. The recommendation to restrict HPV testing to women age 30 and older would reduce the number of women referred for colposcopy because of transient HPV infection.

The ACS guideline also provides relevant recommendations for collecting cervical specimens, including use of an extended-tip spatula to sample the ectocervix and the transformation zone and use of an endocervical brush (rather than a swab) to collect endocervical cells and high transformation zone specimens. Alternatively, a single sample device, such as the cervical broom, can be used to simultaneously sample the endocervix and transformation zone.

Family physicians are encouraged to fully review the ACS and USPSTF cervical cancer screening guidelines and to discuss techniques for liquid-based cytologic specimen collection with their local laboratory or cytologic pathologist. The American Academy of Family Physicians currently is evaluating its prevention recommendations and reviewing the literature on cervical cancer screening.

The Authors

Martin C. Mahoney, M.D., Ph.D., is a member of the Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, N.Y. Dr. Mahoney participated in the Interval, Older Women, and Hysterectomy guideline review workgroup and in the workshop at which the ACS cervical cancer guidelines were discussed.

Debbie Saslow, Ph.D., is director of breast and gynecologic cancers at the American Cancer Society National Home Office in Atlanta, Ga. Dr. Saslow coordinated the guideline review workgroups and developed the 2002 ACS cervical cancer guideline article.

Carmel J. Cohen, M.D., is a gynecologic oncologist and vice chair of the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Medicine at Mount Sinai Medical Center, New York, N.Y. Dr. Cohen was chair of the Gynecologic Cancer Advisory Group that coordinated and developed the 2002 ACS cervical cancer guideline update.

Address correspondence to Martin C. Mahoney, M.D., Ph.D., Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263 (e-mail: martin.mahoney@roswellpark.org).

REFERENCES

1. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer CA Cancer J Clin. 2002;52:342–62

2. U.S. Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. AHRQ Publication No. 03-515A. Rockville, Md.: Agency for Healthcare Research and Quality, 2003.

3. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women J Pediatr. 1998;132:277–84

4. Parazzini F, Negri E, La Vecchia C, Bocciolone L. Screening practices and invasive cervical cancer risk in different age strata Gynecol Oncol. 1990;38:76–80

5. Lynge E, Poll P. Risk of cervical cancer following negative smears in Maribo County, Denmark, 1966–1982. IARC Sci Publ;1986:69–86.

6. Diaz-Rosario LA, Kabawat SE. Performance of a fluid-based, thin-layer papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England Arch Pathol Lab Med. 1999;123:817–21

editor's note: Although the new ACS guidelines on cervical cancer screening are less stringent than the group's previous recommendations, they are more aggressive than the USPSTF guidelines, which, interestingly, have changed little from their 1996 version. Perhaps the most important change in both groups has been to relax the recommended age at which to initiate screening. Recognizing the slow progression of cervical cancer and the low yield of screening among adolescents, both groups recommend waiting up to three years from the onset of sexual activity to begin screening. The numeric minimum age safeguards against possible disease in patients who cannot or will not disclose their sexual history.

The ACS is more stringent than the USPSTF regarding subsequent screening intervals. The USPSTF holds that despite the different pathology of more aggressive HPV subtypes, more frequent testing adds only a slight overall benefit. Finally, because of the concern about false-positive screening results, the USPSTF refrains from making recommendations about the use of new technologies. Physicians who follow the USPSTF guidelines while remaining attentive to the clinical context will prevent cervical cancers in their patients. Many practitioners will choose to follow the more aggressive ACS guidelines, but at least these will reduce excessive screening.—Caroline Wellbery, M.D., Ph.D., assistant deputy editor of American Family Physician, Washington, D.C.

 


Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article